# Aerie Pharmaceuticals Inc. (AERI)

Source: https://www.quantisnow.com/company/AERI
Generated: 2026-11-20T04:45:04.393Z

- Ticker: AERI
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2013
- Website: aeriepharma.com

## About

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

## Latest AERI news and filings

- 2023-02-10 15:00 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aerie-pharmaceuticals-inc-amendment-4038273)
- 2022-12-01 20:07 UTC [SEC Form 15-12G filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-aerie-pharmaceuticals-inc-3757394)
- 2022-11-25 14:47 UTC [Market Insight] [Aerie Pharmaceuticals's Return On Capital Employed Overview](https://www.quantisnow.com/insight/aerie-pharmaceuticalss-return-on-capital-employed-overview-3730836)
- 2022-11-22 06:01 UTC [Dividends] [Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business](https://www.quantisnow.com/insight/alcon-completes-acquisition-of-aerie-pharmaceuticals-inc-strengthening-companys-ophthalmic-3717489)
- 2022-11-21 21:59 UTC [SEC Form 4] [SEC Form 4: Mchugh Julie returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes](https://www.quantisnow.com/insight/sec-form-4-mchugh-julie-returned-245449-worth-of-shares-3716574)
- 2022-11-21 21:57 UTC [SEC Form 4] [SEC Form 4: Mcgraw Benjamin F Iii returned $640,256 worth of shares to the company (41,984 units at $15.25), closing all direct ownership in the company to satisfy tax liability](https://www.quantisnow.com/insight/sec-form-4-mcgraw-benjamin-f-iii-returned-640256-worth-3716558)
- 2022-11-21 21:56 UTC [SEC Form 4] [SEC Form 4: Mcdonnell Peter J returned $121,924 worth of shares to the company (7,995 units at $15.25), closing all direct ownership in the company (for withholding tax)](https://www.quantisnow.com/insight/sec-form-4-mcdonnell-peter-j-returned-121924-worth-of-3716543)
- 2022-11-21 21:54 UTC [SEC Form 4] [SEC Form 4: Kopczynski Casey C. returned $4,273,721 worth of shares to the company (280,244 units at $15.25), closing all direct ownership in the company (withholding tax)](https://www.quantisnow.com/insight/sec-form-4-kopczynski-casey-c-returned-4273721-worth-of-3716527)
- 2022-11-21 21:52 UTC [SEC Form 4] [SEC Form 4: Lang Peter Frederick returned $706,029 worth of shares to the company (46,297 units at $15.25), closing all direct ownership in the company (for withholding tax)](https://www.quantisnow.com/insight/sec-form-4-lang-peter-frederick-returned-706029-worth-of-3716491)
- 2022-11-21 21:47 UTC [SEC Form 4] [SEC Form 4: Larocca John returned $817,171 worth of shares to the company (53,585 units at $15.25), closing all direct ownership in the company to satisfy tax liability](https://www.quantisnow.com/insight/sec-form-4-larocca-john-returned-817171-worth-of-shares-3716408)
- 2022-11-21 21:43 UTC [SEC Form 4] [SEC Form 4: Gryska David W returned $205,738 worth of shares to the company (13,491 units at $15.25), closing all direct ownership in the company (tax liability)](https://www.quantisnow.com/insight/sec-form-4-gryska-david-w-returned-205738-worth-of-3716366)
- 2022-11-21 21:41 UTC [SEC Form 4] [SEC Form 4: Du Toit Michael returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes](https://www.quantisnow.com/insight/sec-form-4-du-toit-michael-returned-245449-worth-of-3716331)
- 2022-11-21 21:37 UTC [SEC Form 4] [SEC Form 4: Croarkin Richard returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company (for withholding tax)](https://www.quantisnow.com/insight/sec-form-4-croarkin-richard-returned-245449-worth-of-shares-3716287)
- 2022-11-21 21:34 UTC [SEC Form 4] [SEC Form 4: Calabrese Jeffrey returned $283,421 worth of shares to the company (18,585 units at $15.25), closing all direct ownership in the company (tax withholding)](https://www.quantisnow.com/insight/sec-form-4-calabrese-jeffrey-returned-283421-worth-of-shares-3716254)
- 2022-11-21 21:30 UTC [SEC Form 4] [SEC Form 4: Kannan Raj returned $3,290,691 worth of shares to the company (215,783 units at $15.25), closing all direct ownership in the company to cover taxes](https://www.quantisnow.com/insight/sec-form-4-kannan-raj-returned-3290691-worth-of-shares-3716174)
- 2022-11-21 16:55 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aerie-pharmaceuticals-inc-3714427)
- 2022-11-21 16:52 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aerie-pharmaceuticals-inc-3714421)
- 2022-11-21 16:47 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aerie-pharmaceuticals-inc-3714400)
- 2022-11-21 16:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aerie-pharmaceuticals-inc-3714340)
- 2022-11-21 16:34 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aerie-pharmaceuticals-inc-3714339)
- 2022-11-21 16:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aerie-pharmaceuticals-inc-3714338)
- 2022-11-21 16:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aerie-pharmaceuticals-inc-3714337)
- 2022-11-21 16:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aerie-pharmaceuticals-inc-3714335)
- 2022-11-21 15:01 UTC [SEC Form 8-K] [Aerie Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aerie-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-3713819)
- 2022-11-18 21:55 UTC [SEC Form 8-K] [Aerie Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/aerie-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-3710388)
- 2022-11-10 21:06 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aerie-pharmaceuticals-inc-amendment-3667431)
- 2022-11-07 22:17 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aerie-pharmaceuticals-inc-3644513)
- 2022-11-07 14:20 UTC [SEC Form 8-K] [Aerie Pharmaceuticals Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/aerie-pharmaceuticals-inc-filed-sec-form-8-k-other-events-3640301)
- 2022-11-03 23:41 UTC [SEC Form 4] [SEC Form 4: Calabrese Jeffrey covered exercise/tax liability with 179 shares, decreasing direct ownership by 0.95% to 18,585 units to satisfy tax liability](https://www.quantisnow.com/insight/sec-form-4-calabrese-jeffrey-covered-exercisetax-liability-with-179-3630940)
- 2022-11-03 21:07 UTC [Market Chatter] [Aerie Pharmaceuticals Q3 EPS $(0.27) Up From $(0.72) YoY, Sales $36.13M Up From $29.31M YoY](https://www.quantisnow.com/insight/aerie-pharmaceuticals-q3-eps-027-up-from-072-yoy-sales-3630084)
- 2022-11-03 20:07 UTC [SEC Form 8-K] [Aerie Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aerie-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-3628568)
- 2022-11-03 20:01 UTC [Earnings] [Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results](https://www.quantisnow.com/insight/aerie-pharmaceuticals-reports-third-quarter-2022-financial-results-3628135)
- 2022-10-07 13:06 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-aerie-pharmaceuticals-inc-3507191)
- 2022-09-21 21:16 UTC [SEC Form PREM14A filed by Aerie Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-prem14a-filed-by-aerie-pharmaceuticals-inc-3439425)
- 2022-09-13 20:01 UTC [SEC Form 8-K] [Aerie Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aerie-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-3406982)
- 2022-09-13 12:00 UTC [Conference Announcement] [Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options](https://www.quantisnow.com/insight/aerie-pharmaceuticals-to-host-key-opinion-leader-event-on-dry-3403543)
- 2022-08-29 14:11 UTC [Market Insight] [Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022](https://www.quantisnow.com/insight/benzingas-top-ratings-upgrades-downgrades-for-august-29-2022-3345859)
- 2022-08-29 11:08 UTC [Analyst Downgrade] [Aerie Pharma downgraded by Citigroup with a new price target](https://www.quantisnow.com/insight/aerie-pharma-downgraded-by-citigroup-with-a-new-price-target-3344391)
- 2022-08-29 09:03 UTC [Market Chatter] [Citigroup Downgrades Aerie Pharmaceuticals to Neutral](https://www.quantisnow.com/insight/citigroup-downgrades-aerie-pharmaceuticals-to-neutral-3343769)
- 2022-08-24 14:11 UTC [Market Insight] [Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022](https://www.quantisnow.com/insight/benzingas-top-ratings-upgrades-downgrades-for-august-24-2022-3326585)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AERI
- Earnings history: https://www.quantisnow.com/earnings/AERI
- Dividend history: https://www.quantisnow.com/dividends/AERI
- Insider transactions: https://www.quantisnow.com/insiders/AERI
- Options chain: https://www.quantisnow.com/options/AERI
- SEC 8-K filings only: https://www.quantisnow.com/company/AERI/8-k
- RSS and alerts for AERI: https://www.quantisnow.com/docs/rss-feeds.md
